ICDcodes.org
FY2027

T36.AX2SPoisoning by fluoroquinolone antibiotics, intentional self-harm, sequela

Billable

Is T36.AX2S billable?

Yes — T36.AX2S is billable for FY2027. T36.AX2S is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. T36.AX2S may be submitted for encounters from October 1, 2026 through September 30, 2027.

T36.AX2S at a glance

CodeT36.AX2S
DescriptionPoisoning by fluoroquinolone antibiotics, intentional self-harm, sequela
BillableYes
Code setICD-10-CM FY2027
Valid for encountersOctober 1, 2026 – September 30, 2027
7th character "S"sequela

What does the 7th character "S" mean in T36.AX2S?

In T36.AX2S, the 7th character S means sequela. The 7th character is required for T36.AX2S to be a valid, complete code.

Same condition, different episode of care — switch the 7th character:

Which MS-DRGs does T36.AX2S group to?

T36.AX2S sits in MDC 21 and helps define the logic of 2 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.

  • 922Other Injury, Poisoning and Toxic Effect Diagnoses with MCCmedical
  • 923Other Injury, Poisoning and Toxic Effect Diagnoses without MCCmedical

Excludes1 — never code together — inherited from T36-T50

The conditions below can never be reported together with T36.AX2S on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

  • toxic reaction to local anesthesia in pregnancy (O29.3-)

Excludes1 — never code together — inherited from T36

The conditions below can never be reported together with T36.AX2S on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.

  • antineoplastic antibiotics (T45.1-)
  • locally applied antibiotic NEC (T49.0)
  • topically used antibiotic for ear, nose and throat (T49.6)
  • topically used antibiotic for eye (T49.5)

Code first — inherited from T36-T50

The underlying condition below must be sequenced before T36.AX2S. T36.AX2S describes a manifestation and cannot be the principal or first-listed diagnosis.

  • , for adverse effects, the nature of the adverse effect, such as:
  • adverse effect NOS (T88.7)
  • aspirin gastritis (K29.-)
  • blood disorders (D56-D76)
  • contact dermatitis (L23-L25)
  • dermatitis due to substances taken internally (L27.-)
  • nephropathy (N14.0-N14.2)

Use additional code — inherited from Chapter 19

Report an additional code alongside T36.AX2S to fully describe the condition. T36.AX2S is sequenced first.

  • code to identify any retained foreign body, if applicable (Z18.-)

Use additional code — inherited from T36-T50

Report an additional code alongside T36.AX2S to fully describe the condition. T36.AX2S is sequenced first.

  • code(s) to specify:
  • manifestations of poisoning
  • underdosing or failure in dosage during medical and surgical care (Y63.6, Y63.8-Y63.9)
  • underdosing of medication regimen (Z91.12-, Z91.13-)

Excludes2 — not included here — inherited from Chapter 19

The conditions below are not part of T36.AX2S, but a patient may have both at the same time. When documentation supports it, T36.AX2S and the excluded code may both be reported.

  • birth trauma (P10-P15)
  • obstetric trauma (O70-O71)

Excludes2 — not included here — inherited from T36-T50

The conditions below are not part of T36.AX2S, but a patient may have both at the same time. When documentation supports it, T36.AX2S and the excluded code may both be reported.

  • abuse and dependence of psychoactive substances (F10-F19)
  • abuse of non-dependence-producing substances (F55.-)
  • immunodeficiency due to drugs (D84.821)
  • drug reaction and poisoning affecting newborn (P00-P96)
  • pathological drug intoxication (inebriation) (F10-F19)

How long has T36.AX2S existed?

T36.AX2S first appears in FY2026.

Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.